Yifan Sun

Yifan Sun

Auto-generated profile, based on publicly available information

Yifan Sun

Department of Medical and Molecular Genetics

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
HXHanchen Xu
Hanchen Xu
KJKevin Van der Jeught
Kevin Van der Jeught
ZZZhuolong Zhou
Zhuolong Zhou
LZLu Zhang
Lu Zhang
TYTao Yu
Tao Yu
XLXiongbin Lu
Xiongbin Lu
One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity, which arises due to lack of immunogenic tumor antigens as well as dysregulation of the antigen processing machinery. In a screen for small-molecule compounds from herbal medicine that potentiate T cell–mediated cytotoxicity, we identified atractylenolide I (ATT-I), which substantially promotes tumor antigen presentation of both human and mouse colorectal cancer (CRC) cells and thereby enhances the cytotoxic response of CD8+ T cells. Cellular thermal shift assay (CETSA) with multiplexed quantitative mass spectrometry identified the proteasome 26S subunit non–ATPase 4 (PSMD4), an essential component of the immunoproteasome complex, as a primary target protein of ATT-I. Binding of ATT-I with PSMD4 augments the antigen-processing activity of immunoproteasome, leading to enhanced MHC-I–mediated antigen presentation on cancer cells. In syngeneic mouse CRC models and human patient–derived CRC organoid models, ATT-I treatment promotes the cytotoxicity of CD8+ T cells and thus profoundly enhances the efficacy of immune checkpoint blockade therapy. Collectively, we show here that targeting the function of immunoproteasome with ATT-I promotes tumor antigen presentation and empowers T cell cytotoxicity, thus elevating the tumor response to immunotherapy.

4 January 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
YFYuanzhang Fang
Yuanzhang Fang
LWLifei Wang
Lifei Wang
CWChanglin Wan
Changlin Wan
YSYifan Sun
Yifan Sun
KJKevin Van der Jeught
Kevin Van der Jeught
XZXinna Zhang
Xinna Zhang
Immune evasion is a pivotal event in tumor progression. To eliminate human cancer cells, current immune checkpoint therapy is set to boost CD8+ T cell–mediated cytotoxicity. However, this action is eventually dependent on the efficient recognition of tumor-specific antigens via T cell receptors. One primary mechanism by which tumor cells evade immune surveillance is to downregulate their antigen presentation. Little progress has been made toward harnessing potential therapeutic targets for enhancing antigen presentation on the tumor cell. Here, we identified MAL2 as a key player that determines the turnover of the antigen-loaded MHC-I complex and reduces the antigen presentation on tumor cells. MAL2 promotes the endocytosis of tumor antigens via direct interaction with the MHC-I complex and endosome-associated RAB proteins. In preclinical models, depletion of MAL2 in breast tumor cells profoundly enhanced the cytotoxicity of tumor-infiltrating CD8+ T cells and suppressed breast tumor growth, suggesting that MAL2 is a potential therapeutic target for breast cancer immunotherapy.

3 May 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
HCHyeongjwa Choi
Hyeongjwa Choi
JKJuntae Kwon
Juntae Kwon
MCMin Soon Cho
Min Soon Cho
YSYifan Sun
Yifan Sun
XZXiaofeng Zheng
Xiaofeng Zheng
CHCecil Han
Cecil Han
Induction of nucleic acid sensing–mediated type I interferon (IFN) has emerged as a novel approach to activate the immune system against cancer. Here we show that the depletion of DEAD-box RNA helicase 3X (DDX3X) triggers a tumor-intrinsic type I IFN response in breast cancer cells. Depletion or inhibition of DDX3X activity led to aberrant cytoplasmic accumulation of cellular endogenous double-stranded RNAs (dsRNA), which triggered type I IFN production through the melanoma differentiation-associated gene 5 (MDA5)-mediated dsRNA-sensing pathway. Furthermore, DDX3X interacted with dsRNA-editing ADAR1 and dual depletion of DDX3X and ADAR1 synergistically activated the cytosolic dsRNA pathway in breast cancer cells. Loss of DDX3X in mouse mammary tumors enhanced antitumor activity by increasing the tumor-intrinsic type I IFN response, antigen presentation, and tumor infiltration of cytotoxic T and dendritic cells. These findings may lead to the development of a novel therapeutic approach for breast cancer by targeting DDX3X in combination with immune-checkpoint blockade. Significance: This study elucidates the novel role of DDX3X in regulating endogenous cellular dsRNA homeostasis and type I IFN signaling in breast cancer.

7 May 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
KJKevin Van der Jeught
Kevin Van der Jeught
YSYifan Sun
Yifan Sun
YFYuanzhang Fang
Yuanzhang Fang
ZZZhuolong Zhou
Zhuolong Zhou
HJHua Jiang
Hua Jiang
XLXiongbin Lu
Xiongbin Lu
Immune checkpoint blockade immunotherapy delivers promising clinical results in colorectal cancer (CRC). However, only a fraction of cancer patients develop durable responses. The tumor microenvironment (TME) negatively impacts tumor immunity and subsequently clinical outcomes. Therefore, there is a need to identify other checkpoint targets associated with the TME. Early-onset factors secreted by stromal cells as well as tumor cells often help recruit immune cells to the TME, among which are alarmins such as IL-33. The only known receptor for IL-33 is stimulation 2 (ST2). Here we demonstrated that high ST2 expression is associated with poor survival and is correlated with low CD8 + T cell cytotoxicity in CRC patients. ST2 is particularly expressed in tumor-associated macrophages (TAMs). In preclinical models of CRC, we demonstrated that ST2-expressing TAMs (ST2 + TAMs) were recruited into the tumor via CXCR3 expression and exacerbated the immunosuppressive TME; and that combination of ST2 depletion using ST2 -KO mice with anti–programmed death 1 treatment resulted in profound growth inhibition of CRC. Finally, using the IL-33trap fusion protein, we suppressed CRC tumor growth and decreased tumor-infiltrating ST2 + TAMs. Together, our findings suggest that ST2 could serve as a potential checkpoint target for CRC immunotherapy.

31 March 2023
Verified
Other
Open access
HCHyeongjwa Choi
Hyeongjwa Choi
JKJuntae Kwon
Juntae Kwon
MCMin Soon Cho
Min Soon Cho
YSYifan Sun
Yifan Sun
XZXiaofeng Zheng
Xiaofeng Zheng
CHCecil Han
Cecil Han

31 March 2023
Verified
Other
Open access
HCHyeongjwa Choi
Hyeongjwa Choi
JKJuntae Kwon
Juntae Kwon
MCMin Soon Cho
Min Soon Cho
YSYifan Sun
Yifan Sun
XZXiaofeng Zheng
Xiaofeng Zheng
CHCecil Han
Cecil Han